Plain Language Summary of ENGOT-EN6/GOG-3031/NSGO-RUBY: A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab + Carboplatin–Paclitaxel Versus Placebo + Carboplatin–Paclitaxel in Recurrent or Primary Advanced Endometrial Cancer

Table of Contents

- General information about this study
  - Why is this study being done?
  - What medicine is being tested?
  - Which patients can enroll?
  - How will the trial be conducted?
  - Where can I find more information?

General information about this study

Why is this study being done?

The RUBY study is being done to see if treatment with dostarlimab plus chemotherapy followed by dostarlimab alone is useful in treating endometrial cancer.

What medicine is being tested?

Dostarlimab is a medicine being tested that is part of a category called programmed cell death inhibitors (or “PD-1 inhibitors”). These drugs help your immune system to find and attack cancer cells.

Which patients can enroll?

Patients must have endometrial cancer that is advanced or recurrent.

How will the trial be conducted?

RUBY is a randomized, double-blind, phase 3 trial. This means that there are 2 treatment options:

1. Standard chemotherapy (the control) Dostarlimab plus chemotherapy (the treatment being tested)

Chemotherapy is a drug treatment that uses powerful chemicals to kill cancer cells in your body. There are two chemotherapy drugs that are used together in this trial: one is called carboplatin, and the other is called paclitaxel.

Where can I find more information?

https://clinicaltrials.gov/ct2/show/NCT03981796